BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20958145)

  • 1. The alkalizer citrate reduces serum uric Acid levels and improves renal function in hyperuricemic patients treated with the xanthine oxidase inhibitor allopurinol.
    Saito J; Matsuzawa Y; Ito H; Omura M; Ito Y; Yoshimura K; Yajima Y; Kino T; Nishikawa T
    Endocr Res; 2010; 35(4):145-54. PubMed ID: 20958145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
    Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
    Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.
    Givertz MM; Anstrom KJ; Redfield MM; Deswal A; Haddad H; Butler J; Tang WH; Dunlap ME; LeWinter MM; Mann DL; Felker GM; O'Connor CM; Goldsmith SR; Ofili EO; Saltzberg MT; Margulies KB; Cappola TP; Konstam MA; Semigran MJ; McNulty SE; Lee KL; Shah MR; Hernandez AF;
    Circulation; 2015 May; 131(20):1763-71. PubMed ID: 25986447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study.
    Alghamdi YS; Soliman MM; Nassan MA
    BMC Pharmacol Toxicol; 2020 Feb; 21(1):10. PubMed ID: 32041665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.
    Sofue T; Inui M; Hara T; Nishijima Y; Moriwaki K; Hayashida Y; Ueda N; Nishiyama A; Kakehi Y; Kohno M
    Drug Des Devel Ther; 2014; 8():245-53. PubMed ID: 24600205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
    J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
    Kohagura K; Tana T; Higa A; Yamazato M; Ishida A; Nagahama K; Sakima A; Iseki K; Ohya Y
    Hypertens Res; 2016 Aug; 39(8):593-7. PubMed ID: 27075830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.
    Liu C; Zhao Q; Zhen Y; Gao Y; Tian L; Wang L; Ji L; Liu G; Ji Z; Liu K
    Can J Cardiol; 2013 Sep; 29(9):1048-54. PubMed ID: 23395281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.
    Kanbay M; Huddam B; Azak A; Solak Y; Kadioglu GK; Kirbas I; Duranay M; Covic A; Johnson RJ
    Clin J Am Soc Nephrol; 2011 Aug; 6(8):1887-94. PubMed ID: 21784838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
    Bove M; Cicero AFG; Borghi C
    Curr Hypertens Rep; 2017 Oct; 19(12):95. PubMed ID: 29071435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Febuxostat on Oxidative Stress.
    Fukui T; Maruyama M; Yamauchi K; Yoshitaka S; Yasuda T; Abe Y
    Clin Ther; 2015 Jul; 37(7):1396-401. PubMed ID: 25913922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.
    De Angelis S; Noce A; Di Renzo L; Cianci R; Naticchia A; Giarrizzo GF; Giordano F; Tozzo C; Splendiani G; De Lorenzo A
    Eur Rev Med Pharmacol Sci; 2007; 11(3):179-84. PubMed ID: 17970234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
    Lee JW; Lee KH
    Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
    Baumgartner S; Yeh LT; Shen Z; Kerr B; Manhard K; Quart B
    J Clin Pharmacol; 2018 Sep; 58(9):1164-1170. PubMed ID: 29733441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of urate-lowering therapies on renal handling of uric acid.
    Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
    Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.